At present, there are driver mutations in nonsmall cell lung cancer (NSCLC), such as epidermal growth factor receptor (EGFR) mutations [1–3], a fusion gene between echinoderm microtubule-associated protein-like 4 (EML4) and the anaplastic lymphoma kinase (ALK) [4, 5], and fusion genes with RET proto-oncogene (RET) [6–8], for which specific agents have been developed. The gene discussed is RET; the disease is non-small cell lung carcinoma.